Thermo Fisher Scientific (NYSE:TMO) Upgraded at UBS Group

UBS Group upgraded shares of Thermo Fisher Scientific (NYSE:TMO) to a strong-buy rating in a report issued on Monday morning, Zacks.com reports.

A number of other research analysts also recently weighed in on TMO. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an equal weight rating on the stock in a research note on Friday, June 28th. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an overweight rating and a $670.00 price target for the company. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an outperform rating in a research note on Thursday, July 25th. Raymond James boosted their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an outperform rating in a research report on Thursday, July 25th. Finally, Jefferies Financial Group reiterated a buy rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of Moderate Buy and an average price target of $632.89.

Thermo Fisher Scientific Stock Down 0.1 %

Shares of NYSE TMO opened at $610.12 on Monday. Thermo Fisher Scientific has a 52-week low of $415.60 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The company’s 50 day moving average price is $596.69 and its 200-day moving average price is $580.98. The company has a market capitalization of $233.07 billion, a P/E ratio of 39.14, a price-to-earnings-growth ratio of 2.86 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the business earned $5.15 EPS. The firm’s revenue was down 1.4% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Brookstone Capital Management increased its position in shares of Thermo Fisher Scientific by 252.4% in the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the period. Artisan Partners Limited Partnership purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $40,335,000. Leo Wealth LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $1,117,000. Rhenman & Partners Asset Management AB boosted its holdings in Thermo Fisher Scientific by 6,600.0% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 33,500 shares of the medical research company’s stock valued at $17,781,000 after acquiring an additional 33,000 shares in the last quarter. Finally, BDF Gestion bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $6,368,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.